Trials / Recruiting
RecruitingNCT06747156
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in patients with refractory autoimmune diseases who received inadequate response or relapsed from standard of care (SoC). The trial included dose escalation and dose expansion parts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABO2203 Injection | Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager |
Timeline
- Start date
- 2024-12-23
- Primary completion
- 2027-11-01
- Completion
- 2028-12-01
- First posted
- 2024-12-24
- Last updated
- 2026-03-24
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06747156. Inclusion in this directory is not an endorsement.